Scisparc Ltd - Asset Resilience Ratio
Scisparc Ltd (SPRC) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Scisparc Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Scisparc Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SPRC total assets.
Liquid Assets Composition Over Time
This chart breaks down Scisparc Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Scisparc Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Scisparc Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Scisparc Ltd Industry Peers by Asset Resilience Ratio
Compare Scisparc Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Scisparc Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Scisparc Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $7.62 Million | -- |
| 2024-12-31 | 5.00% | $517.00K | $10.35 Million | -21.83pp |
| 2023-12-31 | 26.83% | $3.00 Million | $11.18 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $10.61 Million | -- |
| 2010-12-31 | 51.47% | $5.14 Million | $9.98 Million | +1.74pp |
| 2009-12-31 | 49.73% | $6.08 Million | $12.22 Million | +11.90pp |
| 2008-12-31 | 37.83% | $3.79 Million | $10.01 Million | +2.63pp |
| 2007-12-31 | 35.20% | $5.36 Million | $15.22 Million | -10.06pp |
| 2006-12-31 | 45.26% | $5.08 Million | $11.22 Million | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more